氟替卡松和孟鲁司特钠治疗小儿咳嗽变异性哮喘疗效分析

Curative Effect Analysis of Fluticasone and Montelukast Sodium in Children with Cough Variant Asthma

目的探究咳嗽变异性哮喘小儿经氟替卡松、孟鲁司特钠联合用药治疗,其哮喘改善情况。方法选取2015年2月—2017年2月期间门诊治疗的180例咳嗽变异性哮喘(CVA)小儿患者为该文研究对象,根据临床用药不同分为观察组、对照组,其中观察组94例(氟替卡松、孟鲁司特钠联合用药)、对照组86例(仅以氟替卡松治疗),统计治疗期间不良反应情况,观察患儿肺功能、咳嗽症状治疗前后差异,对患者采用门诊随访,随访时间为半年,评估患儿CVA治疗效果以及咳嗽复发情况,检测治疗前后炎性因子白介素-8(IL-8)、白介素-10(IL-10)及Ig E水平变化。结果观察组治疗后IL-8、IL-10、Ig E水平为(25.6±4.3)pg/m L、(32.6±2.4)pg/m L、(137.8±20.5)IU/m L,与对照组(43.6±4.8)pg/m L、(25.4±2.5)pg/m L、(185.2±21.7)IU/m L比较差异有统计学意义(t_1=26.537,t_2=19.708,t_3=15.068,P<0.05);观察组儿童治疗后PEF、咳嗽评分、FEV1/FVC为(196.3±11.7)L/min、(0.5±0.2)分、(63.8±4.5)%,与对照组(172.8±10.2)L/min、(0.9±0.4)分、(74.5±4.1)%比较差异有统计学意义(t_1=14.305,t_2=8.594,t_3=16.623,P<0.05);观察组CVA治疗率为96.8%、复发率为1.1%,与对照组89.5%、7.0%比较差异有统计学意义,(χ_1~2=4.176,χ_3~2=4.479,P<0.05),观察组不良反应发生率为2.1%与对照组3.5%比较差异无统计学意义(χ_2~2=0.360,P>0.05)。结论儿童CVA以FP、孟鲁司特钠联合治疗,患儿肺功能改善、咳嗽减轻,临床治疗效果理想、不良反应少,复发率较低。

Objective This paper tries to explore the improvement of asthma in children with cough variant asthma treated with fluticasone and montelukast sodium. Methods 180 children with cough variant asthma （CVA） during February 2015 to February 2017 outpatient treatment period were selected for this study. According to clinical medica- tions, they were divided into observation group and control group. Among them, 94 cases were observed in the observa- tion group （fluticasone and montelukast sodium）. Medications） and control group 86 patients （only treated with fluticas- one）. Statistical analyze adverse reactions during treatment. Observe differences in the patient＇s lung function and cough symptoms before and after treatment. Outpatient follow-up was performed and the follow-up time was six months. CVA treatment efficacy in children was evaluated. As well as the recurrence of cough, the inflammatory factors interleukin-8 （IL-8）, interleukin-10 （IL-10）, and IgE levels were measured before and after treatment. Results After treatment, IL-8, IL-10 and IgE levels in the observation group were （25.6±4.3）pg/mL,（32.6±2.4）pg/mL, （137.8±20.5）IU/mL, and the control group （43.6±4.8）pg/mL,（25.4±2.5）pg/mL, （185.2±21.7）IU/mL were statistically significant （t1=26.537, t2=19.708, t3=15.068, P〈0.05）; observation group children after treatment, PEF, cough score, FEV1/FVC were （196.3±11.7） L/min, （0.5±0.2） min, （63.8±4.5）%, and the control group （172.8±10.2）L/min, （0.9±0.4）points, （74.5±4.1）% were statistically significant （t1=14.305, t2=8.594, t3=16.623, P〈0.05）. The observation group CVA treatment rate was 96.8%, and the recurrence rate was 1.1%. There was a statistically significant difference between groups （89.5%, 7.0%, X2 1=4.176, X2 3=4.479, P〈0.05）. The incidence of adverse reactions in the observation group was 2.1% compared with 3.5% in the control group （X2 2= 0.360, P〉0.05）. Conclusion Children＇s CVA is treated with FP and montelukast sodium. The children＇s lung function is im- proved and cough is reduced. The clinical treatment effect is ideal, the adverse reactions are less, and the recurrence rate is lower.